![](/images/graphics-bg.png)
Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome
المؤلفون المشاركون
Keating, Matthew
Giscombe, Lisa
Tannous, Toufic
Hartshorn, Kevan
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-09-02
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer.
Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficiencies.
The endpoint of pembrolizumab treatment for patients who enjoy a strong response remains unclear.
Herein, we present the case of a 33-year-old man with pretreated metastatic colon cancer and a prolonged treatment response of over three years to single-agent pembrolizumab even after treatment discontinuation in July 2018.
Prior to pembrolizumab, he was found to have lung and liver metastases despite multiple lines of chemotherapy.
With pembrolizumab, there was a persistent downtrend in CEA level and uptrend in weight.
After nearly three years of pembrolizumab treatment from October 2015 through July 2018, PET scan showed no FDG-avid disease, and further treatment was placed on hold.
He remains under surveillance, with CT scan in February 2019 again showing no evidence of local or metastatic disease.
In patients whose treatment duration and disease course are not defined by toxicities/progressive disease but rather by sustained treatment responses, we propose that immunotherapy treatment duration be guided by close monitoring of CEA levels, weight, and clinical exams in addition to traditional imaging.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Keating, Matthew& Giscombe, Lisa& Tannous, Toufic& Hartshorn, Kevan. 2019. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Keating, Matthew…[et al.]. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Keating, Matthew& Giscombe, Lisa& Tannous, Toufic& Hartshorn, Kevan. Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141932
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1141932
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)